1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 25,600 | 26,200 | 22:18 | |
| 25,800 | 26,000 | 22:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22:12 | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 1 | GlobeNewswire (USA) | ||
| 01.01. | Spyre Therapeutics: Biotech-Aktie mit Potenzial | 731 | sharedeals.de | Die Biotechnologiebranche ist geprägt von einem Spannungsfeld zwischen wissenschaftlicher Innovationskraft und der oft fragilen finanziellen Lage vieler Unternehmen. Umso bemerkenswerter sind Fälle... ► Artikel lesen | |
| 17.12.25 | Mizuho initiates Spyre Therapeutics stock with Outperform rating | 5 | Investing.com | ||
| 17.12.25 | Spyre Therapeutics: Mizuho startet Coverage mit "Outperform" und sieht 60 % Potenzial | 2 | Investing.com Deutsch | ||
| 05.12.25 | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 3 | GlobeNewswire (USA) | ||
| 01.12.25 | Spyre stock rating upgraded to Buy at Jones Trading on TL1A blockade potential | 3 | Investing.com | ||
| 07.11.25 | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 1 | GlobeNewswire (USA) | ||
| SPYRE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.11.25 | Spyre Therapeutics GAAP EPS of -$0.15 beats by $0.61 | 6 | Seeking Alpha | ||
| 04.11.25 | Spyre Therapeutics reports positive interim data for IBD drug SPY003 | 2 | Investing.com | ||
| 04.11.25 | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody | 62 | GlobeNewswire (Europe) | SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (a4ß7 +... ► Artikel lesen | |
| 04.11.25 | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11.25 | Spyre Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 24.10.25 | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 | 1 | GlobeNewswire (USA) | ||
| 15.10.25 | Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million | 1 | GlobeNewswire (USA) | ||
| 14.10.25 | Spyre Therapeutics Stock Rises 11% After $275 Mln Public Offering Pricing | 1 | RTTNews | ||
| 14.10.25 | Spyre Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.10.25 | Spyre Therapeutics prices public offering of 14.8M shares at $18.50 to raise $275M | 1 | Seeking Alpha | ||
| 14.10.25 | Spyre Therapeutics legt Preis für Aktienangebot auf 18,50 US-Dollar fest | 1 | Investing.com Deutsch | ||
| 14.10.25 | Spyre Therapeutics prices public offering at $18.50 per share | 2 | Investing.com | ||
| 14.10.25 | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORUKA THERAPEUTICS | 23,600 | -0,84 % | Oruka Therapeutics: UBS stuft Aktie mit "Buy" ein und sieht 88 % Kurspotenzial | ||
| PALVELLA THERAPEUTICS | 85,50 | -1,16 % | Palvella Therapeutics Inc.: Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs | Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative therapies, including OPZELURA- , povorcitinib, ILUMYA®, ODOMZO- , REMICADE-... ► Artikel lesen | |
| DIANTHUS THERAPEUTICS | 32,800 | 0,00 % | Dianthus Therapeutics, Inc.: Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) | LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress... ► Artikel lesen | |
| LENZ THERAPEUTICS | 15,240 | -6,50 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates | Launched VIZZ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025 Achieved approximately $1.6 million in net... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 294,38 | +0,63 % | Praxis Precision Prices $575 Mln Public Offering At $260/shr | ||
| APOGEE THERAPEUTICS | 77,48 | -1,85 % | Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and ... | Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,830 | +0,73 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,880 | +1,01 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,350 | +26,99 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| VERA THERAPEUTICS | 47,690 | -2,03 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 23,280 | +50,48 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 25,310 | +8,72 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,570 | -1,93 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,000 | -3,21 % | Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting | Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Resolution of Anemia... ► Artikel lesen | |
| ALUMIS | 18,170 | +1,40 % | What's Going On With Alumis Stock Thursday? |
SPYRE THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 26,800 Euro und damit +0,75 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPYRE THERAPEUTICS INC finden Sie auf Wallstreet Online.